Studies have shown that co-delivery of CSF-1R inhibitors with cytokine IL-12 or paclitaxel can remodel the immunosuppressive TME, prompt T cell mediated immunity, and effectively suppress tumor growth and metastasis [228, 229]. The gene discussed is CSF1R; the disease is neoplasm.